Topical GX-03 Shows Promise in Treating Mild to Moderate Eczema
Why this matters
People with atopic dermatitis, often called eczema, know how frustrating flare-ups can be. A new update from Turn Therapeutics looks at an experimental skin cream called GX-03 that’s being tested for atopic dermatitis. The company shared early results from an ongoing phase 2 study, and the findings may be relevant for people whose eczema is very bothersome even if it covers only a small area of skin.
Quick summary
Turn Therapeutics reported an interim review of the first 50 people who completed the trial. The data monitoring committee found that people with lower scores on a standard measurement still had meaningful improvements. That led the study team to rethink how they define who should join the trial. The company says the cream showed signs of working quickly, and some measures suggested it might help people avoid stronger, bodywide medicines later on. These results are early and come from a company announcement, so they should be read with caution.
What the study measured and why that matters
The trial is testing a topical medicine, meaning a cream or ointment applied to the skin, called GX-03 for people with atopic dermatitis (eczema). Two common ways researchers describe how bad eczema is are the Eczema Area and Severity Index (EASI) and the Investigator’s Global Assessment (IGA).
EASI is a score that combines how much skin is involved and how severe the signs are. IGA is a simpler rating clinicians use to describe overall severity. Both tools are useful, but they don’t always match how much a person is suffering.
Why some people with bad symptoms can get a low EASI score
The study’s original rules used EASI and IGA to decide who could join. That could leave out people with severe eczema in a small, important area, like the hands. For example, bad hand eczema can interfere with daily tasks and work but still give a low EASI score because the overall body surface area affected is small. The trial team noticed this and reconsidered how they define “severity” for enrollment.
What the interim review found
The data monitoring committee looked at 50 trial completers and split them into three EASI groups: 1.1–7.0, 7.1–15.9, and 16.0 and above. All three groups showed clinically meaningful improvements, meaning patients’ symptoms and signs improved in ways that matter for daily life. (Source: Turn Therapeutics press release)
Notably, the smallest EASI group (1.1–7.0), which included 32 people, reached statistical significance on the IGA measure despite its size. Turn Therapeutics described this as encouraging, while also warning not to overinterpret early data.
Clearance and possible treatment implications
The company highlighted results for “EASI 100,” which means complete clearance of the eczema measured by the EASI scale. Turn Therapeutics said these clearance numbers may point to an opportunity to treat people earlier and possibly prevent them from needing systemic treatments in the future. Systemic treatments are medicines that work throughout the body, often used when skin-directed therapies aren’t enough. The company’s message is that a safe, fast-acting cream that clears skin might reduce the need for those stronger options later on. (Source: Turn Therapeutics press release)
Speed of relief and the patient experience
One practical finding was that results at week 4 were similar to week 8, which suggests some people may feel better quickly. That matters because faster symptom control can reduce the need for high-potency steroid creams or oral antibiotics when infections occur. The company emphasized speed, safety, and lasting benefit as the commercial focus if GX-03 is ever approved. Again, these are early company-reported results that will need more testing.
Turn Therapeutics’ update came from a company press release and a presentation by the company’s CEO about the trial’s interim analysis. The report describes promising early signals, but it is not the same as final study results published in an independent journal. (Source: Turn Therapeutics press release)
Tracking visible changes
If your eczema causes visible changes, keeping photos or notes about how your skin looks and feels over time can help you and your clinician judge whether a treatment is working. A single short record of changes can be a useful tool before your next appointment.
When to see a doctor
Talk to your dermatologist or primary care provider if your eczema is getting worse, affecting daily activities, causing pain, bleeding, signs of infection (like increasing redness, warmth, pus, or fever), or if you’re unsure about treatment. Only a clinician can recommend whether a skin-directed treatment is right for you or whether a systemic option should be considered.
Disclaimer
This article summarizes an interim analysis reported by Turn Therapeutics. It is not medical advice. Treatment decisions should be made with a clinician. Early, company-reported trial results are promising but need confirmation in larger, peer-reviewed studies before we know how well the treatment really works and how safe it is over time.
Sources
- Turn Therapeutics announces final stage 2 design and data-driven expansion of GX-03 phase 2 program in atopic dermatitis. Turn Therapeutics July 7, 2026. Accessed July 7, 2026. https://ir.turntherapeutics.com/news-releases/news-release-details/turn-therapeutics-announces-final-stage-2-design-and-data-driven